NBIX gets FDA IND acceptance for NBI-1117567 Phase 2 Alzheimer’s cognition
Neurocrine Biosciences, Nxera Pharma’s partner, received FDA IND acceptance for a Phase 2 study of NBI-1117567 targeting Alzheimer’s cognition.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.